Analysts Set Integra LifeSciences Holdings Co. (NASDAQ:IART) PT at $23.00

Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Get Free Report) have been assigned a consensus rating of "Reduce" from the eight analysts that are currently covering the stock, MarketBeat reports. Three investment analysts have rated the stock with a sell rating, four have issued a hold rating and one has assigned a buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $23.00.

Several equities analysts have issued reports on the stock. BTIG Research upgraded shares of Integra LifeSciences from a "sell" rating to a "neutral" rating in a research report on Monday, October 7th. Bank of America cut their price target on shares of Integra LifeSciences from $26.00 to $18.00 and set an "underperform" rating on the stock in a research report on Monday, October 7th. Morgan Stanley initiated coverage on Integra LifeSciences in a research note on Monday, December 2nd. They set an "underweight" rating and a $20.00 target price for the company. Citigroup lifted their price objective on shares of Integra LifeSciences from $16.00 to $22.00 and gave the company a "sell" rating in a research note on Tuesday, November 5th. Finally, Truist Financial cut their price objective on shares of Integra LifeSciences from $26.00 to $21.00 and set a "hold" rating on the stock in a research report on Monday, October 14th.

Integra LifeSciences Stock Performance

Shares of NASDAQ:IART traded up $0.45 on Friday, reaching $26.05. 551,282 shares of the company's stock were exchanged, compared to its average volume of 452,759. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79. The company has a market capitalization of $2.01 billion, a price-to-earnings ratio of -289.41, a PEG ratio of 0.83 and a beta of 1.16. The company has a fifty day moving average of $23.32 and a 200-day moving average of $22.28. Integra LifeSciences has a twelve month low of $16.81 and a twelve month high of $45.42.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last announced its quarterly earnings data on Monday, November 4th. The life sciences company reported $0.41 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.39 by $0.02. The business had revenue of $380.80 million for the quarter, compared to analysts' expectations of $375.81 million. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The firm's quarterly revenue was down .4% compared to the same quarter last year. During the same period last year, the firm posted $0.76 earnings per share. On average, research analysts predict that Integra LifeSciences will post 2.45 EPS for the current fiscal year.

Insider Buying and Selling

In other Integra LifeSciences news, EVP Michael J. Mcbreen sold 1,700 shares of the firm's stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $24.16, for a total value of $41,072.00. Following the completion of the transaction, the executive vice president now directly owns 56,182 shares of the company's stock, valued at $1,357,357.12. This trade represents a 2.94 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 3.10% of the stock is owned by insiders.

Institutional Trading of Integra LifeSciences

A number of large investors have recently modified their holdings of the business. Dimensional Fund Advisors LP boosted its holdings in shares of Integra LifeSciences by 0.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,785,009 shares of the life sciences company's stock worth $52,014,000 after purchasing an additional 12,766 shares in the last quarter. Canada Pension Plan Investment Board bought a new position in shares of Integra LifeSciences during the 2nd quarter valued at $114,000. Thrivent Financial for Lutherans lifted its stake in Integra LifeSciences by 233.9% in the second quarter. Thrivent Financial for Lutherans now owns 56,912 shares of the life sciences company's stock worth $1,658,000 after purchasing an additional 39,868 shares during the last quarter. AXA S.A. grew its stake in shares of Integra LifeSciences by 409.1% during the second quarter. AXA S.A. now owns 96,689 shares of the life sciences company's stock valued at $2,818,000 after buying an additional 77,697 shares during the last quarter. Finally, AQR Capital Management LLC lifted its stake in shares of Integra LifeSciences by 90.9% in the 2nd quarter. AQR Capital Management LLC now owns 611,798 shares of the life sciences company's stock valued at $17,436,000 after acquiring an additional 291,326 shares during the last quarter. Institutional investors own 84.78% of the company's stock.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.